StockData

Zhengye Biotechnology Holding Ltd (ZYBT) stock

ZYBTNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026Score 4/30
$1.52+0.09 (+6.29%)

Close on Nov 17, 2026Market cap $72.03MP/E –Yield –

Zhengye Biotechnology r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was CN¥18.01M, up 40.8% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025CN¥18.01M+40.8%
FY2024Dec 31, 2024CN¥12.79M+7.5%
FY2023Dec 31, 2023CN¥11.90M-11.3%
FY2022Dec 31, 2022CN¥13.42M–

More Zhengye Biotechnology figures

See a number that looks wrong?